Research programme: proteostasis regulators - Proteostasis Therapeutics

Drug Profile

Research programme: proteostasis regulators - Proteostasis Therapeutics

Alternative Names: PTI-130; PTI-C1811; PTI-P271

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Proteostasis Therapeutics
  • Developer Biogen; Cystic Fibrosis Foundation Therapeutics; Harvard Medical School; Proteostasis Therapeutics
  • Class Small molecules
  • Mechanism of Action Alpha-synuclein inhibitors; Cystic fibrosis transmembrane conductance regulator stimulants; Protein folding modulators; Protein modulators; USP14 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Chronic obstructive pulmonary disease; Cystic fibrosis; Neurodegenerative disorders
  • No development reported Inflammation; Metabolic disorders; Parkinson's disease

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for research development in Inflammation in USA (PO)
  • 04 Nov 2017 No recent reports of development identified for research development in Metabolic-disorders in USA (PO)
  • 04 Nov 2017 No recent reports of development identified for research development in Parkinson's-disease in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top